Each year, the Cancer Steering Committee (CSC), led by the Foundation for the National Institutes of Health (FNIH) and its co-chairs Drs. Gary Kelloff (NCI) and Eric Rubin (Merck), brings together experts from academia, pharmaceutical companies, biotechnology companies, not-for-profit organizations, the NIH, and the FDA to participate in a scientific symposium to review advances in the field of biomarker and regulatory science that are relevant to the development of new public-private partnerships for precompetitive biomarkers. The FNIH Biomarkers Consortium’s CSC Symposium thus serves as a juncture each year to assess and recalibrate future directions in biomarker discovery and development.
CRI's Jun Tang, Ph.D., senior manager, CRI Venture Fund and Clinical Accelerator, is presenting the latest update on the PD1/L1 landscape.
View the PD1/L1 Landscape
In 2018, the FNIH and CRI announced that FNIH selected CRI to be its source of landscape intelligence in immuno-oncology. FNIH uses data and analyses from CRI to identify potential trials for PACT and immunotherapy combinations suitable for testing in Lung-MAP.
Learn more about the FNIH-CRI collaboration
The 2019 CSC Symposium will be held on November 4 and 5 at the Bethesda Marriott.
Discuss cutting edge science, including projects supported by the FNIH BC.
Inform the field of the latest developments in critical areas of biomarker science.
Guide CSC decision making and project planning.
Symposium Results & Accomplishments
Demonstrating the diversity of the biomarker science discussed, the previous years' agendas showcased projects across the ecosystem of precision medicine and biomarker development, including MRD, liquid biopsy, novel imaging improvement, cell-free RNA and DNA research, and immuno-oncology. Cross-disease analysis of non-cancer biomarker initiatives also provided discussion to assess approaches for collaboration across the field of medicine. Learn More
Photo by Brian Patrick Tagalog on Unsplash